It was also shown that golimumab, a monoclonal antibody against TNFα can have beneficial effects on endogenous insulin production and exogenous insulin requirements in children and young adults with newly diagnosed type 1 diabetes (53). The gene discussed is INS; the disease is type 1 diabetes mellitus.